Announced details
Rheumatoid arthritis; bone lesions associated with multiple myeloma; bone lesions caused by bone metastases from solid tumors; psoriasis vulgaris; psoriatic arthritis
Golimumab BS: ¥67,615/syringe; Denosumab BS: ¥23,481/vial; Ustekinumab BS: ¥254,206/syringe
The products are positioned as supporting future growth, but no specific amount of impact on financial results is provided.
The company does not address Contract Value.
Official Gazette
| Item | Details |
|---|---|
| Names of Products / Services Covered | Golimumab BS subcutaneous injection 50 mg syringe “F”, Denosumab BS subcutaneous injection 120 mg RM “F”, Ustekinumab BS subcutaneous injection 90 mg syringe “F” |
| Offering price | Golimumab BS: ¥67,615/syringe; Denosumab BS: ¥23,481/vial; Ustekinumab BS: ¥254,206/syringe |
| Applicable area | Rheumatoid arthritis; bone lesions associated with multiple myeloma; bone lesions caused by bone metastases from solid tumors; psoriasis vulgaris; psoriatic arthritis |
| Impact on Business Performance | The products are positioned as supporting future growth, but no specific amount of impact on financial results is provided. |
| Source | Official Gazette |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To give concrete form to the growth of the biosimilar business, one of the growth drivers in the medium-term management plan, and position these products as supporting future growth. The company also cites the provision of new treatment options for patients and healthcare professionals and its contribution to medical economics.